Evidence map›Paper›PMID 33999338›Full record

ArticleInternational journal of hematology2021

Expression of activated integrin β7 in multiple myeloma patients.

Naoki Hosen, Satoshi Yoshihara, Hiroyuki Takamatsu, Masaki Ri, Yasuyuki Nagata, Hiroshi Kosugi, Yoshimitsu Shimomura, Ichiro Hanamura, Shigeo Fuji, Koichiro Minauchi and 16 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors.

Naoki HosenDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamada-Oka, Suita, Osaka, 565-0871, Japan. hnaoki@bldon.med.osaka-u.ac.jp.
Satoshi YoshiharaDivision of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
Hiroyuki TakamatsuDepartment of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
Masaki RiDepartment of Hematology and Oncology, Institute of Medical and Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan.
Yasuyuki NagataDivision of Hematology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Hiroshi KosugiDepartment of Hematology, Ogaki Municipal Hospital, Ogaki, Japan.
Yoshimitsu ShimomuraDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
Ichiro HanamuraDivision of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Japan.
Shigeo FujiDepartment of Hematology, Osaka International Cancer Institute, Osaka, Japan.
Koichiro MinauchiDepartment of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
Junya KurodaDivision of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Rikio SuzukiDepartment of Hematology/Oncology, Tokai University School of Medicine, Tokyo, Japan.
Noriko NishimuraDepartment of Hematology Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Nobuhiko UoshimaDepartment of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
Hirohisa NakamaeDepartment of Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
Yawara KawanoDepartment of Hematology, Rheumatology, and Infectious Diseases, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Ishikazu MizunoDepartment of Hematology, Hyogo Cancer Center, Akashi, Japan.
Hiroshi GomyoDepartment of Hematology, Hyogo Cancer Center, Akashi, Japan.
Kenshi SuzukiDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Shuji OzakiDepartment of Hematology, Tokushima Prefectural Central Hospital, Tokushima, Japan.
Shingen NakamuraDepartment of Community Medicine and Medical Science, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Yoichi ImaiDepartment of Hematology/Oncology, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Masahiro KizakiDepartment of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Eiju NegoroDepartment of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Hiroshi HandaDepartment of Hematology, Gunma University Graduate School of Medicine, Maebashi, Japan.
Shinsuke IidaDepartment of Hematology and Oncology, Institute of Medical and Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma (MM) is still extremely difficult to cure, and new therapeutic drugs are needed. We recently found that integrin β7 is constitutively activated in MM cells, and chimeric antigen receptor (CAR) T cells targeting activated integrin β7 have a significant anti-MM effect. In this study, we performed flow cytometry analysis of the expression of activated integrin β7 in bone marrow cells from 137 symptomatic MM patients. In 60/137 (44%) MM patients, activated integrin β7 was detected in most MM cells (> 80% of MM cells were in the positive gate). Activated integrin β7 was highly expressed in MM cells even in heavily treated patients. It also showed high expression in many CD38

Indexed as

AgedBone Marrow CellsFemaleFlow CytometryHumansImmunotherapy, AdoptiveIntegrin beta ChainsMaleMultiple MyelomaPlasma Cellsintegrin beta7Integrin beta ChainsCAR T cellsIntegrinMultiple myeloma

Identifiers

PMID33999338

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.